Bladder Cancer Response to Bacillus Calmette-Guérin May Be Linked to Urine Microbiome
New evidence suggests variation in the bacterial composition of urine is associated with response BCG among patients with non-muscle-invasive bladder cancer.
Diagnosis & Disease Information
Investigational Antiandrogen Drug Delays Metastasis in CRPC
Among men with nonmetastatic castration-resistant prostate cancer, those who were treated with darolutamide had a 59% decreased risk of metastasis compared with placebo recipients.
Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer
At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.
Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
Newer mCRPC Drugs Led to Longer Survival in African American Patients
The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
Metastatic Prostate Cancer Responds to Novel Radiation Therapy
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
PCa Genomic Test May Predict Outcomes More Accurately in African-American Men
The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium 2019
Loading... 
Loading...